Latest / CME Outfitters Medical Education / Expanding Access – Optimizing Use of Long-Acting Injectable PrEP
Transcript
- 0:00SPEAKER_03: Hello and welcome.
- 0:01SPEAKER_03: On behalf of CME Outfitters, I'd like to welcome and thank you for joining us.
- 0:06SPEAKER_03: This activity is titled Expanding Access or Optimizing Use of Long Acting Injectable Prep and addresses global considerations, not just local considerations, but really thinking about this across the world.
- 0:20SPEAKER_03: This is a program that's supported by an independent educational grant from Gilead Sciences.
- 0:26SPEAKER_03: So today's activity may include discussion of products or devices that are not currently labeled for use by the United States FDA.
- 0:36SPEAKER_03: And as a reminder, again, this is a program that's dedicated to thinking about things across the planet.
- 0:42SPEAKER_03: So indications may vary by regulatory authorities across the world.
- 0:46SPEAKER_03: So clinicians should consult local guidance to confirm approved labeling.
- 0:52SPEAKER_03: So I'm David Wool, and I'm delighted to be joined by an incredibly super panel of discussants today that are going to share with me their thoughts.
- 1:03SPEAKER_03: So I'm going to start with having our panelists introduce themselves, and I'm going to start with Dr.
- 1:08SPEAKER_03: Boomerang, and we'll allow each of these faculty to introduce themselves, tell us a little about themselves, and then we'll launch into the program.
- 1:16SPEAKER_03: So, Fair, I'm going to start with you, if it's okay.
- 1:19SPEAKER_03: And we're going to be using first names, so um, you know, everyone will get very familiar with each other.
- 1:24SPEAKER_03: Um, but let's start with you, Fair, and tell us about yourself.
- 1:28SPEAKER_00: Hi, thank you, Dr.
- 1:29SPEAKER_00: Wolf.
- 1:30SPEAKER_00: And um good morning, good afternoon, good evening, everybody.
- 1:33SPEAKER_00: My name is Jakapat Bundryang O'Fair.
- 1:36SPEAKER_00: I am a research physician affiliated with the Institute of HIV research and innovation in Bangkok, Thailand.
- 1:43SPEAKER_00: I provide sexual and reproductive health services, including PrEP, PEP, STI prevention and treatment.
- 1:50SPEAKER_00: But I am also privileged to be included as a sub-investigator in HPT and OEC3 and purpose to studies as well.
- 1:59SPEAKER_00: It's very nice to know you and to be talking in this panel.
- 2:03SPEAKER_01: Hi David, I'm Cristina Musini.
- 2:05SPEAKER_01: I'm a full professor of infectious diseases, and I'm the chief of the Clinic of Infectious Diseases at the University of Modena Erregia Emilia in Italy.
- 2:16SPEAKER_01: I'm also a member of the Governing Council of IAS, and I'm the vice chair of the section on antiretrovirus of the uh European AIDS Clinical Society.
- 2:33SPEAKER_02: Hi everyone, I'm Landon Meyer.
- 2:35SPEAKER_02: I'm a professor of epidemiology and biostatistics in the School of Public Health at the University of Cape Town.
- 2:40SPEAKER_02: I'm a primary care physician and I work largely in maternal and child health services, antenatal and postnatal care, as well as sexual reproductive health care for women in high HIV burdened communities in South Africa, and work uh a lot in prevention and treatment issues uh facing these populations.
- 3:01SPEAKER_03: So, our learning objective for today is listed here differentiate between long-acting injectable prep options, including optimal patient selection criteria, transitioning strategies, and monitoring considerations.
- 3:18SPEAKER_03: Thinking about which drugs and which um people and how to match them together.
- 3:25SPEAKER_03: That's really what we're talking about.
- 3:26SPEAKER_03: And then once we do decide upon a strategy, what's involved with that, right?
- 3:32SPEAKER_03: What's entailed, uh including monitoring and the types of things we have to worry about as far as toxicities or intolerance.
- 3:38SPEAKER_03: So we'll be getting more deeply into some of these questions as we move forward, right?
- 3:44SPEAKER_03: So the first one, of course, is candidacy.
- 3:46SPEAKER_03: Who's the right person for prep?
- 3:49SPEAKER_03: Um, and so this has been something, again, that a lot of us have been thinking about, and again, at different parts of the world, we may think about this a little bit differently.
- 3:56SPEAKER_03: So I I'm gonna first choose uh Landon and I'm gonna ask, you know, Lennon, uh looking at when we think about uh who is, you know, who do you think where you are and what you're thinking about, which is really an important place to think about prevention, of course, but thinking about like who's the right person, who stands to benefit the most from PrEP, and especially from long-acting PrEP.
- 4:21SPEAKER_03: Because a lot of what we're talking about today is how do we think about PrEP within the context of newer choices vis-a-vis long-acting injectable PrEP.
- 4:31SPEAKER_02: Yeah, David, happy to share my thinking.
- 4:33SPEAKER_02: And I, you know, obviously we're here because everyone at increased risk of HIV acquisition needs to be thinking about PrEP with their providers.
- 4:41SPEAKER_02: And and that's true of long-acting agents in my from my perspective as well.
- 4:46SPEAKER_02: That is, long-acting agents have some uh they're incredibly efficacious, um, and they have some really desirable properties that almost any any uh die out of a patient, a provider should be thinking about long acting.
- 4:59SPEAKER_02: And the the issue that we grapple with, and I think uh many regions of the world grapple with, is one of access.
- 5:05SPEAKER_02: That is, if if there's limited access for structural reasons, for financial reasons, for whatever set of health systems reasons, how do we think about patient prioritization?
- 5:13SPEAKER_02: How do we think about uh who may benefit the most?
- 5:18SPEAKER_02: So everyone can benefit, but who would benefit the most?
- 5:21SPEAKER_02: And and there I think this slide does a great job of outlining some of the of the populations that might stand to benefit um in excess from um from long actings.
- 5:34SPEAKER_02: Um people who have demonstrated challenges with oral PrEP is a is clearly uh a great population to start with, because presumably these are patients, in my experience, who want to take PrEP, who are interested in PrEP, and for whatever set of reasons, um it might overlap with some of the psychosocial issues around seeking discretion to reduce stigma, or for other reasons, they're struggling with oral prep.
- 5:57SPEAKER_02: And for me, that's a a great starting place in terms of prioritizing long actings because you've got a patient population who knows about PrEP, who appreciates PrEP, and then may um may struggle with orals and can take the next step into long actings.
- 6:12SPEAKER_02: Um and so so for me, people established on PrEP making a transition is a is who are struggling is a good place to start, certainly.
- 6:21SPEAKER_03: Yeah, no, I was just gonna ask you a little bit more about that, because I think that's that's great.
- 6:25SPEAKER_03: But a minority of people take it, and you've you've had experience now giving long-acting injectable prep to people in South Africa.
- 6:32SPEAKER_02: And you know, I I want to say I think it's important to recognize that that oral prep is is great.
- 6:37SPEAKER_02: And when when, like a lot of or daily oral agents, when taken regularly, they're highly efficacious.
- 6:42SPEAKER_02: It but we know that that uh across all treatment modalities, not just around HIV prevention, people often struggle to take daily treatments.
- 6:49SPEAKER_02: Right.
- 6:49SPEAKER_02: Um and so the, as you say, the the hand raisers are a really important group.
- 6:55SPEAKER_02: And what we find is that the in transitioning to long actings, the uh the people who are established on orals and and want to transition make for a very adherent long-acting patient population because they appreciate the uh the modality that they're receiving.
- 7:13SPEAKER_02: They know the alternative in a sense, um, and uh and appreciate the the treatment modality, appreciate less frequent clinic visits, appreciate the discretion and potential for reduced stigma.
- 7:23SPEAKER_02: Um and so I think that's a very good starting place to think about.
- 7:28SPEAKER_02: It's certainly not the only one, however, because there are people who may be initiating PrEP who, for different sets of reasons, uh would certainly benefit from long actings in particular.
- 7:39SPEAKER_02: Um and the the groups that I work with and and think about a lot are mainly women, women of reproductive age, either during pregnancy and postpartum or outside of the context of pregnancy.
- 7:52SPEAKER_02: Um and and there's sort of two issues that I wanted to surface here.
- 7:56SPEAKER_02: The the first is to recognize that pregnancy and postpartum is a time of radical changes in lives and in a woman's life and in her circumstances and living circumstances, sleep circumstances, and the ability to adhere to any daily therapy or daily prophylaxis.
- 8:14SPEAKER_02: And so it stands to reason and it resonates with our experience that long actings could fit in well in this context.
- 8:21SPEAKER_02: And then in the postpartum period is a place that I really believe that long actings have a particular niche that women we're recognizing are at increased risk of transition in many communities.
- 8:33SPEAKER_02: There's new partner acquisition, um, there's ongoing breastfeeding transmission risk if there's seroconversion taking place.
- 8:39SPEAKER_02: And so there's a really good rationale to have highly efficacious PrEP in the postpartum period.
- 8:44SPEAKER_02: And that dovetails with the second sort of um issue in women's health that I think long actings are are uh positioned to key into, which is the tradition of injectable contraceptives.
- 8:57SPEAKER_02: Across sub-Saharan Africa, um, there's a very strong um practice of administering injectable contraceptives.
- 9:04SPEAKER_02: And so women of reproductive age are well familiar with the notion of taking uh uh going to the clinic or seeing a provider to um to have a Q3 month or Q six month injection or a Q2-month injection in some instances.
- 9:18SPEAKER_02: And so so there's almost a tradition that uh in in many parts of the world, certainly in South Africa, that we're seeing long actings feed into for women of reproductive age.
- 9:31SPEAKER_03: Yeah, no, it's great.
- 9:32SPEAKER_03: And I love the idea of piggybacking on opportunity and also, of course, the scaffolding of contraception.
- 9:38SPEAKER_03: Of course, some people may not know about which agents we're exactly talking about and what the options are now.
- 9:45SPEAKER_03: So I think fair, if maybe I'm gonna call on you and ask you to maybe walk us through a little bit because there are a bunch of different options, and you've been intimately involved in helping to study and compare these different modalities for prep.
- 10:00SPEAKER_03: So maybe here we can kind of just think a little bit about what's on the menu, what's on what are the options that we have that we can select from?
- 10:08SPEAKER_00: Definitely, David.
- 10:09SPEAKER_00: Thank you very much.
- 10:10SPEAKER_00: And yes, we are fortunate um that we are now living in the era where exciting new innovations on PrEP are blooming.
- 10:19SPEAKER_00: Before we had oral regimens of PrEP, we have two of them, actually, TDF FTC and TAF FTC or TAF FTC, which are effective prevention tools on their own right.
- 10:31SPEAKER_00: For TDF FTC, oral PrEP can be used in a daily and on-demand or even driven manner.
- 10:39SPEAKER_00: Um it is a very soft medication, but still poses some effects on kidney functions and mineral density, while TAF FTC had less effects on LED.
- 10:49SPEAKER_00: However, we are introduced quite recently with long-acting injectable PrEP, including Cabo Fear or CAP LA, and LENACOPAVER LON-Acting CREP or LEN.
- 11:01SPEAKER_00: Both of these innovations have superior prevention efficacies than compared to the oral TDF-FTC daily regimen.
- 11:09SPEAKER_00: The differences were CAP LA requires an intramuscular injections every two months, except from the first month where the injections would be one month apart.
- 11:19SPEAKER_00: And LEN actually requires subcutaneous injections every six months.
- 11:24SPEAKER_00: We also have depiven vaginal ring as well, which has a modest efficacy, but can be locally administered by inserting through vaginal canal every month.
- 11:36SPEAKER_03: Yeah, for sure.
- 11:37SPEAKER_03: Thank you for that overview.
- 11:38SPEAKER_03: So, and I think it's important that you pointed out that you know the comparative studies, including those that you've been involved with, you know, do show that a long-acting injectable PrEP actually performs better than oral prep.
- 11:52SPEAKER_03: And largely that's due to adherence.
- 11:54SPEAKER_03: I, you know, I think that's important to recognize that it's not so much that molecularly that there's one that's more potent than the other, but that it's just much more acceptable to folks.
- 12:04SPEAKER_03: So I think that's pretty consistent even in clinical practice subsequently, reflecting the preference data that we already just started to talk about, which I think is pretty clear.
- 12:14SPEAKER_03: So, you know, the first, you know, uh long-acting injectable, as you mentioned, was a cab integraer for prep.
- 12:23SPEAKER_03: And uh, Christina, I'm gonna ask you to think a little bit about this with us.
- 12:26SPEAKER_03: And I know you know we we in the US really are adhere to the Department of Health and Human Services guidelines.
- 12:33SPEAKER_03: You have the ECE updates and the ECE recommendations.
- 12:37SPEAKER_03: And I think um it'd be helpful for us to understand a little bit about what uh what's been updated more recently about long-acting injectable prep with CAB attagravir.
- 12:47SPEAKER_03: And I know that it's not only the efficacy data that have motivated some of the recommendations regarding CAB LA, but also some of the data regarding stigma, um, disclosure, and even patient satisfaction uh in in people who have been in the studies that have gotten CAB.
- 13:08SPEAKER_03: So maybe you just highlight a little bit from Eeks, you know, what what they've updated more recently regarding long-acting injectable CAB.
- 13:17SPEAKER_01: Yeah, David, uh during the last uh Paris conference, uh we have uh shown the 21st uh update uh version updated version of the EX guidelines.
- 13:31SPEAKER_01: I have to say that uh we had a huge discussion because at that time uh it neither Kabotagrave nor Lena Kapavir were available in Europe.
- 13:41SPEAKER_01: And so we and usually we don't recommend anything that is not available in the continent.
- 13:50SPEAKER_01: Uh, while we decided that uh we wanted to be positive, and uh we decided to include long acting prep in the updated version.
- 14:03SPEAKER_01: I have to say that uh we tried to cover all the aspects, as you said, because there are very positive aspects that are, you know, the decrease in stigma, because we don't have only to think about stigma of people living with HIV, but also people who are on prep, uh they uh they think that their uh sexual life uh is under scrutiny when they come and that they under, I mean, there could be people who are judgmental.
- 14:39SPEAKER_01: And uh so I I really think that uh you know uh even just uh not taking the pill either on demand or every day uh helps you in uh uh in a way in uh facing uh uh in a positive way the stigma.
- 14:59SPEAKER_01: On the other hand, and also the preference, because I think that it's very important that you know trials, I mean, uh I heard uh talking about women, you know, as London said, in you know, uh we all the oral prep trials on women failed, because they they didn't take it.
- 15:23SPEAKER_01: So it's not surprising that women really, either because they have uh they are familiar with injection, with the contraception, or because of stigma, or because they don't have to have pills all around the house when they have kids or whatever, you know, I think that it's very important for them to have it's really a huge opportunity.
- 15:49SPEAKER_01: Um the other hand, uh we have also challenges.
- 15:54SPEAKER_01: We don't have to forget that we have challenges.
- 15:57SPEAKER_01: We have uh challenges concerning, for example, the risk of failure and of resistance.
- 16:04SPEAKER_01: I I still think that uh, you know, as the data uh showed, uh people, especially women uh but also men who really were uh adherent to schedule, to injection schedule, the risk of failure was very, very, very low.
- 16:25SPEAKER_01: Even zero infection in those who really adhere among women.
- 16:30SPEAKER_01: So I think that this is something that should be kept in mind.
- 16:34SPEAKER_01: On the other hand, we know that uh if the administration is more erratic, we know that we have a tail, a tale of cabotegravi, uh as we were saying about uh some PK issues.
- 16:49SPEAKER_01: We have a tale that could last even for one year.
- 16:52SPEAKER_01: So if uh we have to be very careful in counseling and telling uh people that if they discontinue injectables, uh they could acquire HIV in the presence of the drug and so developing resistance.
- 17:09SPEAKER_01: So it's very important that there is a transition to the aura very, very soon.
- 17:16SPEAKER_01: And so uh, and also the fact that there is a development of uh um genotypic resistance uh associated to the drugs that are in uh in first line in all the guidelines, it's also something that should be evaluated.
- 17:38SPEAKER_01: On the other hand, we have the great data on uh patient satisfaction and the impact on the quality of life.
- 17:49SPEAKER_01: I mean, I think that injectables are for those who really want them.
- 17:57SPEAKER_03: Yeah, no, that's a great point.
- 17:58SPEAKER_03: I really like what you said.
- 17:59SPEAKER_03: And I think it's really important to not prejudge whether or not somebody will say yes or no to an injectable and that it should be more universally offered because our own biases or filters may get in the way of equitable offering of newer advances in therapeutics and prevention.
- 18:18SPEAKER_03: So I think it's a really important point.
- 18:19SPEAKER_03: Uh but I think it comes back to, and again, the Eeks and US Public Public Health Service guidelines and uh in the United States and others, they look at data.
- 18:29SPEAKER_03: Um, and real briefly, maybe just like give us a an a minute of an overview, but we've talked about, we're gonna talk about four major trials in the next few minutes, and and two of them have to do with cabotecavir, and that's the HPTN studies 083 and 084.
- 18:44SPEAKER_03: These are really incredible studies.
- 18:46SPEAKER_03: I mean, like remarkable studies of the decade.
- 18:48SPEAKER_03: So I know it's a tall order, but Christina, if you can just give us a thumbnail sketch for a minute or so about 083 and 084 and why they're so important and why they did put caboteavir on the map.
- 19:00SPEAKER_01: Yeah, I think that uh it's very important because these are two phase, uh, two, three trials, and uh they were double dummy.
- 19:10SPEAKER_01: So the results that they have uh are really reliable.
- 19:14SPEAKER_01: And uh in HPTNO83, uh the population was uh was composed by chief gender men who have sex with men and transgender women who have sex with men, and uh with a high likelihood of acquiring HIV because uh they they were enrolled in country with a high incidence to HIV, that is Argentina, Brazil, we know that Peru, we know that we have uh a very big problem in South America, South Africa, Vietnam, Thailand, and in the US.
- 19:52SPEAKER_01: Um while the HPTNO84 uh included women and women in Africa.
- 19:59SPEAKER_01: So um Botswana, Ezwatini, Kenania, Malawi, South Africa, Uganda, Zimbabwe.
- 20:06SPEAKER_01: As I already talked about how it's challenging to have uh uh oral PrEP in women.
- 20:14SPEAKER_01: So it's not surprising since uh uh both trial you know um versus oral prep that uh the results in women was even more relevant than in men who have sex with men.
- 20:30SPEAKER_01: Um because it was 88% of reduction in HIV incidence among women, and I have to say that for those who adhere to the schedule of injection, it was zero infection.
- 20:43SPEAKER_01: So this is very, very uh important.
- 20:46SPEAKER_01: And also when they look at the few cases, um one case uh of infection was at baseline.
- 20:55SPEAKER_01: So even less that it was reported, it was four, so it was actually three during the trial.
- 21:02SPEAKER_01: While among MSM and transgender women, uh the incidence reduction was 68%, both of them were you know uh were really superior.
- 21:15SPEAKER_01: Both trials were superior to OLA PrEP.
- 21:18SPEAKER_01: And also in uh in uh men who have sex with men and transgender women, we had one of the infections that was the baseline case.
- 21:28SPEAKER_01: So I think that having two huge trials, two really uh um, you know, uh milestone as a trial, both showing superiority to oral PrEP is not something that should be excluded from guidelines.
- 21:51SPEAKER_01: And so I think that this is something that we have to keep in mind and uh it's very, very important.
- 21:59SPEAKER_01: And The tolerability was very good, it was just the injection site reaction, but this is normal, it's an injection, so it's uh uh but uh the rate of discontinuation was very, very low.
- 22:13SPEAKER_03: Yeah, no, great, wonderful.
- 22:15SPEAKER_03: So, really, two very important trials showed the superiority of CAP compared to um oral PrEP, and I think really important studies in basically all different types of people that you can imagine using PrEP in.
- 22:29SPEAKER_03: So, fair.
- 22:30SPEAKER_03: I I think you know that was great, and that put long-acting injectables on the map, as we said.
- 22:36SPEAKER_03: But then then we have Lenocapravir, so which is the next drug that became under scrutiny and tested in clinical trials.
- 22:46SPEAKER_03: I think a lot of people don't realize that there's a twice-a-year injection that can prevent HIV infection.
- 22:52SPEAKER_03: So maybe just walk us similarly through long-acting injectable PrEP with Len, and again, have looked at Lena Capavir and interrogated it across a broad diverse population that could benefit from PrEP.
- 23:07SPEAKER_03: So I'll turn it over to you.
- 23:10SPEAKER_00: Right.
- 23:10SPEAKER_00: And Lena Capavir, I think, follow the footsteps of what have been conducted with Cap LA.
- 23:16SPEAKER_00: They learned a lot, um, I believe, from the first ever um long-acting injectable prep such as CAP LA.
- 23:24SPEAKER_00: So Lena Capavir also consists of two pivotal studies as well, purpose one and purpose two.
- 23:30SPEAKER_00: Uh, as for purpose one, that um the this study will consist of the study population on cisgender women in South Africa and in Uganda, while purpose two study covers a wider range of populations there, including cisgender men, transgender women, transgender men, and gender non-binary individuals who have sex with the partners outside male at birth.
- 23:56SPEAKER_00: However, the efficacy of Lenica BR when compared to the oral PrEP, whether it be FTDF or FTAF, is very much astounding because in purpose one study, there are no incident HIV infection at all amongst this gender women in South Africa and Uganda, which is mind-blowing.
- 24:16SPEAKER_00: Um, such amazing innovations.
- 24:19SPEAKER_00: However, in purpose two, we also find a few um HIV incidence cases, but that also contribute to the reductions of 96% of HIV incidences when compared to the baseline HIV incidents in the country that the study has been conducted.
- 24:37SPEAKER_00: So those are um the summary, a very bird-eye views of purpose one and purpose two.
- 24:44SPEAKER_00: Generally, Lenacovia is a very well-correlated innovation.
- 24:49SPEAKER_00: But of course, there is no innovation without limitations.
- 24:52SPEAKER_00: So in purpose two, we have commonly seen, of course, adverse events, particularly injection site pain, node's and redness.
- 25:00SPEAKER_00: However, they are mostly miles.
- 25:02SPEAKER_00: However, we do know that only 1% has discontinued the study because of this injection site reactions.
- 25:09SPEAKER_00: So, in a way, we can imply that um Lenica Pavier is a very well-trialated innovation.
- 25:17SPEAKER_03: Yeah, no, thank you.
- 25:18SPEAKER_03: That's great.
- 25:18SPEAKER_03: Again, so really wonderful.
- 25:20SPEAKER_03: Landon, I might just ask you just a little bit of an editorial comment, if you will, on purpose one and purpose two and what what is meant for you.
- 25:29SPEAKER_02: David, if I if I might uh editorialize, I think four things really come to mind when I think about the purpose trials.
- 25:36SPEAKER_02: The the first is, as Fair said, the the remarkable efficacy.
- 25:41SPEAKER_02: The second thing is the increased efficacy or evidence, both in CAB and Len, for increased uh efficacy in women versus men.
- 25:50SPEAKER_02: Again, very different, as Christina says, from some of the other data that we we're accustomed to seeing and and that I think is exciting in that regard and maybe needs a little bit of unpacking over time.
- 26:01SPEAKER_02: The the third thing I'd say is about the pregnancy data, um, because there's a lot of concern about the pregnancy data, and and and it's important to look at safety signals, absolutely.
- 26:14SPEAKER_02: Um, and and as far as we know from the best available evidence, there there aren't safety signals right now.
- 26:20SPEAKER_02: Um, and phase four work has to keep going, of course.
- 26:22SPEAKER_02: But but it this is uh this by all accounts is a safe uh safe agent in women of reproductive age.
- 26:28SPEAKER_03: So just recapping, we have two great options for people.
- 26:32SPEAKER_03: We have long-acting injectable cab, cabotegra, and then we have long-acting injectable lenacappavir.
- 26:38SPEAKER_03: The differences as we highlighted, you know, both work really well compared to oral prep, which definitely had its limitations, and people voted with their injection sites.
- 26:48SPEAKER_03: Um, so it's great.
- 26:50SPEAKER_03: Um, but there are differences, right?
- 26:51SPEAKER_03: So CAB LA, which came out first, is IM.
- 26:54SPEAKER_03: Um, we give a dose of IM, and then a month later another dose of IM, and then we're off to the races every two months.
- 27:01SPEAKER_03: With twice yearly Lenacapavir, there's some differences in the injection site reaction, as Fair mentioned, and I think those are important.
- 27:08SPEAKER_03: Um, more short-lived with CAB than with Lenacapavir, which those nodules can persist.
- 27:14SPEAKER_03: So that's where we are.
- 27:16SPEAKER_03: So, what about what's coming down the pike?
- 27:20SPEAKER_03: Um, because again, we've we've we've had this a great advance over the last few years from taking a pill a day basically to prevent your HIV, which a lot of people struggle to do, especially those who don't take any other pills, who consider themselves healthy and don't really even see a doctor very often, um, to now, you know, something that could be taken, like we said, like contraception intermittently and with a shot.
- 27:44SPEAKER_03: Um, but there's probably even room to go, as I think we can all imagine, and maybe the perfect prep we haven't achieved yet.
- 27:53SPEAKER_03: So I think some of the key considerations now that we should focus on, now that we talked about who's the right person and what are the products that are available that weren't available before.
- 28:05SPEAKER_03: Um, but I do do also think we have to think a little bit about sort of the mechanics of initiating prep, especially long-acting prep, and how how that can differ in some ways than what we've been used to before.
- 28:18SPEAKER_03: So, Fair, I might start with you again, just going sort of in order of what we've talked about before, is some of the key considerations when initiating PrEP now, and some of the things we have to think about, what we should really be paying attention to.
- 28:33SPEAKER_00: Definitely.
- 28:34SPEAKER_00: Um, thank you.
- 28:35SPEAKER_00: So, um, of course, we are looking at HIV testing before we start anything, including oral prep as well.
- 28:43SPEAKER_00: But that is where the discrepancy happens because guidelines across the world um recommend different things for HIV negative status for innovations such as long-acting injectable prep.
- 28:57SPEAKER_00: So, in some countries in the world, they would recommend HIV NAT tests because that's of course is more accurate in terms of detecting HIV infections.
- 29:07SPEAKER_00: But in some resource limiting countries, such as in the Southeast Asian countries, we might not be able to do so.
- 29:14SPEAKER_00: So we might have to rely on the fourth generation and DHIV testing instead.
- 29:20SPEAKER_00: And this allows resource limiting settings to be able to scale up low-active injectable prep by utilizing the similar infrastructure as they had before for oral prep.
- 29:32SPEAKER_00: So I think uh fourth generation and DHIV testing in resource limiting country is a very good um way to go.
- 29:42SPEAKER_03: And let me ask you a quick question, Fair, because this comes up a lot for us is um how long before you give the injection do you want to see uh a negative test?
- 29:53SPEAKER_00: Luckily for our settings in Thailand, um, we are able to get the result back in one hour.
- 29:59SPEAKER_00: So the result is quite fast.
- 30:01SPEAKER_00: Um, that might not be true with all the different settings, but uh with us, uh we don't have to answer that hard questions where we have to, you know, kind of leverage the waiting period of time.
- 30:13SPEAKER_00: Um so one hour is actually acceptable uh in our clients' perspective.
- 30:20SPEAKER_02: Yeah, no, it's the same, it's just uh one week.
- 30:23SPEAKER_02: To concur with FAIR, sort of the the um the allowance for fourth generation antigen antibody testing really enables implementation in low resource settings in a way that isn't necessarily an issue in Europe or North America.
- 30:37SPEAKER_02: Um and so same-day testing is routine in in our setting.
- 30:41SPEAKER_02: And and if we couldn't use same-day testing, it would be a major health systems barrier to implementation.
- 30:47SPEAKER_02: Um and and our approach is is really to initiate prep with the client in front of you on the end on the day, because often you can lose people.
- 30:57SPEAKER_02: Um and so to uh to do what you can uh in the moment.
- 31:01SPEAKER_03: So maybe I could just ask again, each of you, um, whether you know it could be what you're doing or what you think should be done if you're not doing it right now, because again, everywhere LEN is still just rolling out.
- 31:14SPEAKER_03: So Lynn, I'm gonna start with you.
- 31:16SPEAKER_03: Um any thoughts about the cadence of HIV testing given the newer modalities?
- 31:20SPEAKER_02: Yeah, I I think part of the problem with understanding the cadence of monitoring with LEN is that we don't have enough experience with breakthrough infections because it's so efficacious.
- 31:29SPEAKER_02: And that's it's it's kind of a we're cut by our own sword in that sense, is that we we don't know what to do because we haven't seen enough of it.
- 31:36SPEAKER_02: Um and long may that continue.
- 31:38SPEAKER_02: But but I think uh a six-monthly, you know, uh testing at the next injection is it just seems sensical from my per perspective.
- 31:47SPEAKER_02: Um, in the absence of good data on LEN, because we don't have enough infections.
- 31:50SPEAKER_02: I I think it makes sense.
- 31:51SPEAKER_02: What I think it will do in country programs is push country programs or or districts or services to either CAB or LEN rather than to, in a given patient population, have a mix of them.
- 32:02SPEAKER_02: Because that could lay, you could imagine, that could lead to a little bit of chaos and implementation.
- 32:06SPEAKER_00: In my view, I think every six months screening for chlamydia, gonorrhea, and syphilis is sensible and it um ties in perfectly with Linica Tavier, but we can remain pragmatic.
- 32:17SPEAKER_00: So, for example, a person comes in and they have symptoms, they can visit the clinics earlier and make that clear that clinics are not um actually for every six months, but it can be more frequent than that if the sexual behavior calls for it.
- 32:32SPEAKER_00: So I think we can look at it differently this time where we can assess things separately.
- 32:39SPEAKER_03: Yeah, that's great.
- 32:41SPEAKER_03: So we're talking mostly about initiating and then monitoring.
- 32:46SPEAKER_03: We should recognize, of course, that there's a bunch of people who are on oral prep who now, once injectable prep becomes available, are interested in switching what to do when switching from oral to injectable.
- 32:59SPEAKER_03: And one one I think important thing to recognize is that one of the nice things about the injectables that I think most people don't appreciate is the level of protection you get is is achieved very, very, very quickly.
- 33:14SPEAKER_03: Um, so it's not like there has to be built up over a long period of time an accumulation of drug, and then you start to get the protection.
- 33:24SPEAKER_03: When you look at the PK for both Lenin Cabot tegavir, it is remarkable how high the levels are, even within the first day of administration, right?
- 33:35SPEAKER_03: Coordinate this so that it makes a lot of sense that we don't want them to stop their oral prep, you know, a month beforehand, you know, those kind of things that I think just make a lot of sense.
- 33:45SPEAKER_03: Um, we we've talked about oral lead-in for lena capovir.
- 33:48SPEAKER_03: We haven't talked about oral lead-in for cabotegovir, which was in the initial clinical trials.
- 33:53SPEAKER_03: That was much more for a safety tolerability, not really for a PK.
- 33:57SPEAKER_03: And so we've learned you don't really adverse events like allergic reactions, things like that to cabotecavir, it just hasn't really become an issue.
- 34:07SPEAKER_03: So doing an oral lead-in to kind of test um for caboteir, we don't need to do that.
- 34:12SPEAKER_03: We you can just go to direct to inject.
- 34:14SPEAKER_03: But for leno capavir, we do need that oral dosing to try to kick start the levels that we've been talking about.
- 34:22SPEAKER_03: And then, you know, once that occurs, then we can then transition just to the injectable and get on that cadence we were talking about.
- 34:29SPEAKER_03: Um, I I just want to check in with our faculty.
- 34:31SPEAKER_03: Any thoughts about that or anything to add or your own experiences?
- 34:36SPEAKER_01: No, we agree.
- 34:37SPEAKER_01: Okay.
- 34:38SPEAKER_01: We totally agree that uh everybody has the right to say no.
- 34:42SPEAKER_01: I think that this is a very important sentence.
- 34:46SPEAKER_03: No, so don't don't let that get in your way.
- 34:48SPEAKER_03: Don't let that be an obstacle.
- 34:50SPEAKER_03: Um, you know, we talked about, you know, this I'm glad we kind of jumped on this before about the STI screening and fair.
- 34:57SPEAKER_03: You brought up some really good points about being pragmatic about it.
- 35:00SPEAKER_03: I don't think we have to go too much in detail, um, but we do have an opportunity here to think not just about HIV.
- 35:08SPEAKER_03: Um, and I do agree Lena Capavir is so efficacious.
- 35:11SPEAKER_03: I'm not worried about people acquiring HIV over the six-month time period between their injection and their next injection.
- 35:18SPEAKER_03: But we are worried, of course, about people acquiring syphilis or gonorrhea chlamydia.
- 35:23SPEAKER_03: And again, I think that there's been some guidance about what's the right um again, cadence and screening for sexually transmitted infections.
- 35:32SPEAKER_03: And again, that differs now, the opportunity to test for that.
- 35:36SPEAKER_03: So, Fair, anything you want to add to that?
- 35:38SPEAKER_03: Because I know you think about this a lot.
- 35:40SPEAKER_00: Yes, that's it.
- 35:42SPEAKER_00: So, of course, I agree.
- 35:43SPEAKER_00: We we have to remain pragmatic, but also prioritize SDIs as well.
- 35:48SPEAKER_00: Uh, what um I think is possible as well is to do self-testing for STIs.
- 35:53SPEAKER_00: We are now having a lot of combos between HIV, Syphilis Chlamydia, and Gonrhea self-collections, and even self-testing.
- 36:00SPEAKER_00: We can actually utilize that if these innovations will also be included in the national guidelines and international guidelines that would be that would change the landscape of how we look at STIs um around the world.
- 36:16SPEAKER_00: So that's going to reach people even in places where we can they cannot access um physically to the clinic too.
- 36:24SPEAKER_00: So I think there are a lot to gain if we were to just explore um these options in the future.
- 36:31SPEAKER_03: Wonderful.
- 36:32SPEAKER_03: I think there's guidance that is in the package inserts for each of these products that I think spell this out, um, that I think are a great place to um look at some of the details.
- 36:44SPEAKER_03: Um but again, I do think it's important for people to recognize that there are going to be situations where people either have a plan to delay, I'm gonna be out of town, and you have to come up with a plan B for those people proactively, or you might be in a situation where somebody something happens and somebody has missed a dose and now it's you know outside the window of where you think that that protection from the previous dose would still be present.
- 37:11SPEAKER_03: So be familiar with this, know what to do, know that your staff knows what to do, and I think that will get you in good stead because people are complicated.
- 37:20SPEAKER_03: This will happen.
- 37:21SPEAKER_03: My only point here is that we have to recognize that there are a lot of these drivers of health that are structural.
- 37:30SPEAKER_03: So, uh fair, I might choose you because I think that you probably work in an environment that's very different, I heard already, um, from the one in which I work, um, which is which is definitely challenging.
- 37:42SPEAKER_03: Um so maybe you could talk a little bit about social drivers of health and how that plays out in your own practice, again, vis-a-vis the delivery of PrEP and long-acting PrEP.
- 37:52SPEAKER_00: And now we are changing that landscape.
- 37:54SPEAKER_00: So, of course, there will be fractures um in the system.
- 37:58SPEAKER_00: So, for example, in Southeast Asian region, our main rollout modes would be through community clinics.
- 38:05SPEAKER_00: And with that said, it means that this clinic does not even have physicians or sit-in nurses in the space, which makes it impossible to provide injections.
- 38:16SPEAKER_00: So there are a few factors that can contribute to these fractures.
- 38:20SPEAKER_00: The first one would be the infrastructure-dependent delivery.
- 38:24SPEAKER_00: As I said, long-acting PrEP requires a place where injectors, clinical oversight, and um monitoring can be done on-site.
- 38:33SPEAKER_00: Secondly, is access limitations.
- 38:36SPEAKER_00: So, you uh, what PrEP used to be in our region is through community-led clinics, through pharmacies, outreach models, to rural settings, and those might not be able to accommodate uh injections.
- 38:49SPEAKER_00: So we really have to think hard about how we can bring those long-acting innovations to the place where it is needed the most.
- 38:58SPEAKER_00: The third thing is, of course, the shift in control.
- 39:01SPEAKER_00: The next one is, of course, the regional readiness gaps.
- 39:06SPEAKER_00: And the last thing, the most important ones actually, is the cost, um, not only with the drug price, but also the cost of the training, capacity building, different infrastructures, um, and also policy updates, too.
- 39:19SPEAKER_00: So all of these things combined can prevent people who needed these innovations from take from getting it.
- 39:27SPEAKER_03: Yeah, and that's wonderful.
- 39:29SPEAKER_03: Yeah, I think that's really insightful.
- 39:31SPEAKER_03: And and Landon and Christina, maybe Len, you first and any drivers in South Africa that that differ or that you want to highlight, and then Christina, I'm gonna ask you the same thing about your experience in Italy.
- 39:42SPEAKER_02: The one thing I would I would um want to emphasize is that regarding patient level barriers, we we know from from antifetroviral therapy adherence and from treatment compliance studies for decades, providers do a very bad job of predicting who will be adherent.
- 40:00SPEAKER_02: Um and and really the the patient provider dyad, that that that uh joint decision making is is what should really drive um drive the engagement.
- 40:11SPEAKER_02: And and so one of the things we're really loath to do is to is to put in the hands of providers some adjudication of the social barriers, which patients may or may not be able to um to adhere to long actings, um, and to really see that as uh to give the patients agency um in their own treatment decision making.
- 40:29SPEAKER_03: Yeah, absolutely.
- 40:30SPEAKER_03: Christina, what about you in Italy?
- 40:33SPEAKER_01: In Europe, we are struggling to have reimbursement of these drugs, and because the cost in Europe is evaluated when it's compared to oral prep that is now generic.
- 40:46SPEAKER_01: So this is a huge problem.
- 40:49SPEAKER_01: But uh for now, it's not routinely possible to prescribe it.
- 40:55SPEAKER_01: So this is the major barrier, I think.
- 40:58SPEAKER_01: And uh we will see in the next future.
- 41:02SPEAKER_03: Yeah, no, absolutely.
- 41:04SPEAKER_03: Um, so as we wrap up over the next uh couple of minutes, I just I'm just gonna ask each of you, you know, just a little bit maybe for pearls or tips about, and I know some of this we've mentioned before, but it even could be based upon your own research or your own experience and clinical practice, but maybe just you know, a clinical tip about PrEP, about initiating, transition monitoring, or you know, even paying for it, as Christina mentioned, um, anything that you can kind of share with us that might be a tip for how to make this happen.
- 41:36SPEAKER_03: So, um Christina, since you have the floor, I'm gonna ask you anything that that you're doing that might be worthwhile sharing?
- 41:44SPEAKER_01: I mean, I think that uh what we have seen from the uh court of people on prep in Italy is that uh uh when you are at the first year, you have 40% risk of discontinuation that uh increases to 70% after four years.
- 42:02SPEAKER_03: Great.
- 42:02SPEAKER_03: And we heard a lot from Landon already about this.
- 42:04SPEAKER_03: So fair, I'm gonna ask you uh any sort of tips when we think about this that you would share with others and thinking about starting and continuing people on prep.
- 42:14SPEAKER_00: If we can instue that resilience or that education into the clients, they can switch back and forth between history preventions.
- 42:22SPEAKER_00: So even if they stop using PrEP, of course they can fall back to condoms.
- 42:26SPEAKER_00: We don't we don't have to forget about condoms, right?
- 42:29SPEAKER_00: And clients don't need to do that as well.
- 42:31SPEAKER_00: So I want like to see strategies where we can incorporate resilience into our clients.
- 42:38SPEAKER_03: Yeah, no, that's that's wonderful.
- 42:40SPEAKER_03: I I really like that.
- 42:41SPEAKER_03: And I think that's a perfect segue to thinking more about patient education.
- 42:46SPEAKER_03: I like what you said.
- 42:47SPEAKER_03: I mean, I think you know, today we've talked about who's the optimal patient and how we select those, how we transition the nitty-gritty of the details of the drugs and switching from oral to long acting, monitoring, including HIV and STIs, and then the challenges of implementing.
- 43:04SPEAKER_03: But I love that you've added on to that this whole idea of like, well, but also we need the client to be educated and understand.
- 43:12SPEAKER_03: That's part of that shared decision making, right?
- 43:14SPEAKER_03: So shared decision making is informed decision making.
- 43:18SPEAKER_03: And so I think patient education tools are really helpful here.
- 43:22SPEAKER_03: And and different people have different ones that they've created, and some are better than others, but I do help think that there's a a usefulness to having something that you can hand to people or go over with people as you talk to them.
- 43:36SPEAKER_03: Um and so I think the tools that are available, and there's tools that that have been created that I think we can reference here on CME Outfitter's website that I think could be very useful.
- 43:47SPEAKER_03: And I like that they're graphic, because I think people respond visually to graphics more so than just words on paper.
- 43:54SPEAKER_03: So I think this is again another wonderful resource.
- 43:57SPEAKER_03: And and just taking it, you know, again, from the perspective of the person who could benefit from PrEP, here's some insight from a real person who spent time both in Asia and Europe.
- 44:08SPEAKER_03: And as we wrap up, I think this quote kind of brings us home to what we've been talking about.
- 44:14SPEAKER_03: And and again, uh we talk about it in where I work in my clinic.
- 44:19SPEAKER_03: It's a lot of work.
- 44:20SPEAKER_03: Um you've spent a lot of time here listening to us today.
- 44:23SPEAKER_03: But if everything that you did, all this effort leads to one person not getting HIV infected, it's all worth it, right?
- 44:33SPEAKER_03: So these are things that I think again, you can take home, think about, implement, and hopefully this would be utilized in a positive way for you and for everyone else.
- 44:43SPEAKER_03: So thank you again to our faculty for sharing amazing insights and thank you to our audience for taking the time out to improve your understanding of PrEP and new PrEP modalities.
- 44:54SPEAKER_03: We encourage you to explore the additional resources that are linked with this activity.
- 45:00SPEAKER_03: Continue the conversation in your own practices like we are all the time.
- 45:04SPEAKER_03: We also invite you to visit the CME Outfitters Infectious Disease Hub, which includes free evidence-based resources for both healthcare professionals and for patients.
- 45:15SPEAKER_03: These are tools that are designed to support practical implementation of the concepts that we discussed today, including a status neutral HIV screening and prevention approach.
- 45:26SPEAKER_03: Now, this activity is part of a broader HIV prevention education series.
- 45:30SPEAKER_03: Additional programs will explore other topics, and we encourage you to explore these programs on your own and build on what we discussed today.
- 45:39SPEAKER_03: So, again, I want to thank all of you.
- 45:42SPEAKER_03: Before we wrap up, just a quick reminder that to receive CME or CE credit, you'll need to complete the post-test and evaluation online.
- 45:50SPEAKER_03: Once completed, you'll be able to download and print your certificate immediately.
- 45:55SPEAKER_03: Thanks again for your participation.
- 45:56SPEAKER_03: And thank you again for our international esteemed uh faculty who've um different time zones and you know everyone's getting ready for different things.
- 46:07SPEAKER_03: But thank you very much for sharing your knowledge and really honesty today.